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Background: Direct-acting antiviral (DAAs) agents for hepatitis C virus (HCV) span a variety of targets, including
proteins encoded by the NS3/4A, NS4B, NS5A, and NS5B genes. Treatment with DAAs has been shown to select
variants with sequence changes in the HCV genome encoding amino acids that may confer resistance to the
treatment. In order to assess these effects in patients, a Reverse Transcription Polymerase Chain Reaction (RT-PCR)
method was developed to sequence these regions of HCV from patient plasma.
Methods: A method was developed to amplify and sequence genotype 1 HCV RNA from patient plasma.
Optimization of HCV RNA isolation, cDNA synthesis, and nested PCR steps were performed. The optimization of
HCV RNA isolation, design of RT-PCR primers, optimization of RT-PCR amplification conditions and reagents, and the
evaluation of the RT-PCR method performance is described.
Results: The optimized method is able to successfully, accurately, and reproducibly amplify near full-length
genotype 1 HCV RNA containing a wide range of concentrations (103 to 108 IU/mL) with a success rate of 97%. The
lower limit of detection was determined to be 1000 IU/mL HCV RNA.
Conclusions: This assay allows viral sequencing of all regions targeted by the most common DAAs currently in
development, as well as the possibility to determine linkage between variants conferring resistance to multiple
DAAs used in combination therapy.
Keywords: Hepatitis C Virus (HCV), Reverse Transcription Polymerase Chain Reaction (RT-PCR), Genotype, Direct
Acting Antiviral Agents (DAA), Lower Limit of Detection (LLOD), Quasispecies, Sequencing, Resistance, NS
(Non-structural), NS3/4A, NS4B, NS5A, NS5BBackground
More than 170 million people (3% of the world popu-
lation) are infected with hepatitis C virus (HCV) [1].
Chronic HCV infection is a major cause of liver
cirrhosis and hepatocellular carcinoma (HCC), as well
as liver failure. Liver failure is one of the most common
indications for liver transplantation in the United States
[2,3]. The recent development of potent, direct-acting
antiviral agents (DAAs), used in combination with
pegylated-interferon (Peg-IFN) and ribavirin (RBV) has* Correspondence: Tara_Kieffer@vrtx.com
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reproduction in any medium, provided the orsignificantly improved the sustained virologic response
rates compared with Peg-IFN and RBV alone [4,5].
HCV has high genetic variability across the six major
genotypes as well as in different subtypes within each
genotype. Genotype 1, the predominant cause of chronic
HCV infections in the United States, Europe, and Japan,
has more diversity within subtypes 1a and 1b than the
entire diversity of HBV and HIV [6]. In an HCV-infected
patient, this pre-existing genetic variability provides a
pool of variants that can adapt to new selection pres-
sures, such as antiviral treatment. The variants are a nat-
ural part of the viral quasispecies, which arise from the
error-prone nature of the HCV RNA-dependent RNA
polymerase and the high replication rate of the virus [7].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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men, the elimination of the majority of the DAA-
sensitive quasispecies can lead to selection and detection
of DAA-resistant variants [8].
The nonstructural (NS) HCV proteins NS3, NS4A,
NS4B, NS5A, and NS5B are essential for viral replication
and are the major targets of DAAs currently in develop-
ment [9]. Thus, monitoring viral sequence changes
across multiple NS regions is beneficial in understanding
the potential association between therapeutic resistance
and clinical outcome [10].
Various methods for amplification and sequence analysis
of specific HCV genomes have been reported, and
most of them have focused on individual NS segments
or smaller amplicons [11-14]. In 2006, a long reverse
transcription polymerase chain reaction (RT-PCR) ampli-
fication protocol of a near full-length HCV genome was
developed by Fan, X, Xu, Y, and Di Bisceglie, AM,
that amplified a limited number of patient samples
[15-17]. While conducting telaprevir (INCIVEK™,
INCIVOW) clinical trials [18,19], the need arose to de-
velop a method to analyze the HCV genotype 1 se-
quence of NS3, NS4A,NS5A, and NS5B from a single
genome or the catalytic domain of the NS3•4A protease
domain from a large number of patients. The challenge
was that samples from patients are extremely variable
and existing methods described in the literature required
patient-by-patient optimization to efficiently amplify
near full-length HCV RNA, particularly in samples with
low HCV RNA levels, which were common in patients
who were responding to telaprevir and/or VX-222. In
this study, we describe the development of an efficient
RT-PCR method that was used in telaprevir clinical trials
to amplify a nearly full-length HCV genotype 1 genome
from 7800 unique patient samples containing a wide
range of HCV RNA concentrations (103 to 108 IU/mL)
with a success rate of 97% [4,5,20-23]. This method
enables HCV genes, targeted by the most common
DAAs in clinical trials today, to be efficiently sequenced
using clinical samples with low HCV RNA levels and
permits the assessment of linkage between multiple
amino acid changes in different HCV genes in samples
from patients receiving DAA drug combinations.
Results and discussion
Optimization of HCV RNA extraction
The use of the 96-well format QIAamp Virus BioRobot
9604 Kit (QIAGEN, Valencia, CA) was optimized to pro-
duce high-quality viral RNA from HCV RNA-positive
plasma. Several modifications were made, with the primary
change involving the replacement of the carrier RNA in the
RNA isolation. Comparison of the use of poly A RNA (rA)
provided in the QIAGEN kit with transfer RNA (tRNA)
(Roche Applied Science, Indianapolis, IN) or ribosomalRNA (rRNA) (Roche Applied Science, Indianapolis, IN)
using plasma samples with a wide range of HCV RNA copy
numbers (10 ~ 18,500 HCV RNA copies/reaction) showed
that 60 μg of tRNA per column for 660 μL plasma led to
the highest level of sensitivity in the subsequent amplifica-
tion reaction. In addition, several other minor changes to
the standard QIAamp protocol also increased viral RNA
purity and quality, which helped the performance of subse-
quent amplifications including mixing via gentle rocking, in-
stead of pipetting (per the BioRobot 9604 Kit protocol), to
minimize shearing of the 9.6 kb HCV RNA. Also, for opti-
mal recovery of viral RNA, the samples were lysed at 56°C
and an additional spin step was added following the final
wash step to eliminate residual ethanol carry-over.
cDNA synthesis
Synthesis of cDNA is a critical step in the ability to amp-
lify large PCR products, such as the 9.6 kb HCV gen-
ome. Optimization of the cDNA synthesis from HCV
RNA involved testing different oligonucleotide primers
including random hexamers, oligo d(A) (20 nucleotide),
and primers that annealed in the NS5B or 3’ untrans-
lated region (UTR). Surprisingly, most of the primers
binding in the NS5B or 3’UTR did not allow amplifica-
tion of full-length viral RNA or lead to very low cDNA
yields. In contrast, oligo dA20, which anneals to the
highly conserved poly (U) tail at the 3’ end of the HCV
RNA, did allow for high sensitivity and reproducible
amplification of full-length cDNA. We also tested several
conditions and concentrations of Reverse Transcriptase
enzyme (Superscript™ III Reverse Transcriptase [Life
Technologies Corporation, Carlsbad, CA]) and it was
determined that the use of 400 units with a 2.5 hour
protocol, containing increasing annealing/elongation tem-
peratures, was preferred.
Amplification of HCV via nested PCR
To amplify sufficient amounts of the HCV genome for
subsequent sequence analysis, PCR primers and condi-
tions were optimized. Using several hundred publicly
available genotype 1 HCV sequences (Los Alamos HCV
Sequence Database [24]), the regions of highest conser-
vation in the 5’ and 3’UTRs were selected for potential
primer annealing sites. Subsequent evaluation of primers
to the conserved regions showed a diversity of responses
in the assay. Many primers resulted in either a poor
PCR yield, potentially due to the secondary structure of
HCV RNA in the binding region, or a poorer than
expected effectiveness across a spectrum of multiple
samples. The highest performing primer annealing sites
were at base pair (bp) 242–271 in the 5’UTR and bp
9278–9305 in the NS5B coding region. When various
primer lengths were investigated, the use of 28–30 bp
oligonucleotide primers led to the highest sensitivity and
Table 1 List of primers used for the amplification of the
HCV coding region
RT primer Oligo d(A) 5’-AAAAAAAAAAAAAAAA
AAAA-3’
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potentially annealing to viral genomes with several nu-
cleotide mismatches from the primer. Also, to increase
the ability to amplify across a spectrum of samples from
a large number of patients, some degeneracy was added
in the least conserved nucleotides in each annealing
region. Differences in the primer annealing regions be-
tween subtypes 1a and 1b led to the design of subtype-
specific primers (Table 1). Conditions with the largest
impact on assay performance included the use of a
touchdown PCR method (ramping annealing tempera-
tures) for increased specificity, and addition of a second
nested PCR reaction to increase the sensitivity of the
assay to ~1000 IU/mL of HCV RNA (Figure 1). The com-
bination of a highly processive polymerase (KlenTaq1™)
with a proofreading (pfu) polymerase, and addition of
1.5 M betaine increased the yield of the ~9000 bp PCR
product. Betaine is likely acting through the reduction ofFigure 1 Primer locations. RT, PCR1 and PCR2 primers were designed ba
position of these primers is shown.the bp composition dependence on DNA strand melting
[25,26].
Sensitivity of RT-PCR amplification
To assess the sensitivity of the method, four genotype 1
HCV RNA-positive plasma samples (two subtypes 1a and
two subtypes 1b) were serially diluted with concentrations
of HCV RNA ranging from 11–649,000 IU/mL, and two
analysts performed the amplification on different days.
The HCV RNA-positive plasma samples were processed
through the RT-PCR step and subsequent PCR amplifica-
tions were performed in triplicate. Samples with HCV
RNA greater than or equal to 1000 IU/mL had an amplifi-
cation success rate of 70% (100 out of 143 samples) in the
first attempt. Samples with HCV RNA below 1000 IU/mL
had a much lower amplification success rate of 1.6% (2 out
of 121 samples). Therefore, the lower limit of detection
(LLOD) of the RT-PCR amplification method was estab-
lished to be ~1000 IU/mL. No significant differences in
success rates were observed either between subtype 1a and
1b samples or between analysts.
Robustness and success rate of amplification and
sequencing
The performance of the assay was subsequently evaluated
on a large, diverse set of plasma samples containing HCV
subtypes la or lb from telaprevir and VX-222 clinical trials,
with HCV RNA titers ranging from 100 IU/mL to greater
than 107 IU/mL (Table 2). We processed 7800 unique pa-
tient plasma samples containing subtype 1a (5400) and
subtype 1b (2400) with HCV RNA at or above the assay
limit of detection of 1000 IU/mL from August 2006 to De-
cember 2010. The genetic diversity of both subtypes 1a
and 1b sample sets was similar to sample sets in the public
domain (Los Alamos HCV Sequence Database [24]) as
shown in Table 3 (Shannon Entropy [27], BioEdit version
7.0.5.3). The majority (~97%) of subtype 1a and subtype
1b samples were successfully amplified, and usually on thesed on H77 for subtype 1a and Con1 for subtype 1b, and the relative
Table 2 Summary of RT-PCR amplification and
sequencing success rate of clinical samples from















≥ 1000 1a 5400 97 (5238/5400) 99.6 (5218/5238)
1b 2400 97 (2328/2400) 99.6 (2318/2328)
100–1000 1a 152 48 (73/152) 98.6 (73/73)
1b 107 40 (43/107) 100.0 (43/43)
aHCV RNA was assessed using the Roche TaqMan HCV RNA assay (Version 2.0).
bGenotype and subtype was defined using 5'NC assay (Trugene) or Versant
HCV genotype assay (LiPA) 2.0.
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to amplify, no correlation with HCV RNA level was
observed. The failure of the assay was likely due to high
sequence diversity in one or more of the primer binding
regions, caused by either the natural high variability in
genotype 1 samples, or mis-genotyping of the samples.
Testing of samples below the 1000 IU/mL assay limit of
detection, including samples as low as 100 IU/mL, led to a
lower success rate (48% and 40% for subtypes 1a and 1b,
respectively), and were not pursued further. Among the
amplified samples, nearly 99% of the samples were suc-
cessfully sequenced with a small set of standardized se-
quencing oligonucleotides, and the sequence information
was consistent across replicates. The remaining 1% of
samples for which sequence was not available had the
highest sequence diversity in the areas of interest, leading
to poor annealing for the sequencing oligonucleotides.Conclusion
Despite the high sequence diversity of HCV, successful
amplification of a near full-length (~9 kb) HCV genotype
1 genome was completed on 97% (7566/7800) of patient
plasma samples with HCV RNA concentrations greater
than or equal to 1000 IU/mL. This method facilitated
the examination of sequence changes in the viral popu-
lation during DAA treatment and aided the development
of telaprevir [28]. The ability to amplify and sequenceTable 3 Comparison of HCV NS3(4A) region of Los Alamos an
Subtype Sequence domain Number of sequences° Leng
1a Los Alamos Sequences 695
Vertex Sequences 2111*
1b Los Alamos Sequences 561
Vertex Sequences 1335†
° Sequences of HCV NS3(4A) region.
* GenBank accession numbers: KC125008-KC127118.
† GenBank accession numbers: KC123434-KC124768.the near full length HCV genome and to look at muta-
tions across multiple DAA targets will be important in
the development of multiple DAA-based regimens.
Methods
Studies included in these analyses were conducted in full
compliance with the guidelines of Good Clinical Practice
and of the World Medical Assembly Declaration of Hel-
sinki. Prior to study initiation, protocols and informed
consent forms were reviewed and approved by institu-
tional review boards at each study site. All patients pro-
vided written informed consent before participating in
any study-related activity. ClinicalTrials Identifiers for
studies included in the manuscript are as follows:
NCT00336479, NCT00372385, NCT00420784, NCT00-
535847, NCT00627926, NCT00983853, NCT00758043,
NCT00916474, NCT00528528, NCT00703118, NCT00-
911963, NCT01080222.
This method is based on the amplification protocol
originally described in Kwong et al. [29].
HCV RNA extraction
Viral RNA was extracted from plasma in a 96-well format
according to the manufacturer’s instruction with several
modifications. Plasma (220 ~ 660 μL, the volume was
adjusted based on viral load, i.e., 220 μL for HCV RNA
greater than or equal to 50,000 IU/mL, while 660 μL for
HCV RNA less than 50,000 IU/mL) was mixed with QIA-
GEN Protease K (40 ~ 120 μL) and QIAamp AL buffer
(240 ~ 720 μL) supplemented with 20 ~ 60 μg of carrier
RNA (tRNA) per column. The mixture was incubated for
15 min at 56°C, and absolute ethanol (293 ~ 875 μL) was
added to each well and mixed well. The mixture was
loaded into QIAamp column and passed through the col-
umn by suction with a peristaltic micropump (IPS-16;
Ismatec, Zurich, Switzerland). Subsequently, the column
was washed with AW1 buffer (1000 μL) and AW2 buffer
(1000 μL) (provided in QIAGEN kit), respectively, by ap-
plying vacuum. A second wash with AW2 buffer (1000
μL) was spun at 6000 × g for 10 min and an additional
spin at 6000 × g for 15 min was applied to remove residual







2067 0.132014 7.5% (± 1.9%)
2085 0.175243 9.1% (± 4.6%)
2067 0.158275 9.3% (± 1.5%)
2085 0.202466 10.6% (± 3.4%)
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temperature for 5 min. The RNA was eluted by centrifu-
gation at 6000 × g for 10 min. The elution was repeated
once to increase the yield. A total of 80 μL viral RNA was
isolated from 220 to 660 μL of plasma.
cDNA synthesis
A complementary DNA (cDNA) fragment was synthe-
sized from HCV RNA that was diluted (1:2 or 1:4, the
dilution factor was based on viral load, i.e., 1:2 and 1:4
for HCV RNA less than 50,000 IU/mL, while 1:4 for
HCV RNA greater than or equal to 50,000 IU/mL) into
a total RT reaction volume of 20 μL composed of 2.5
μM of an oligo-dA20 primer (Table 1), 400 units of
Superscript™ III Reverse Transcriptase (Life Technologies
Corporation, Carlsbad, CA), 40 units of RNAseOUT (Life
Technologies Corporation, Carlsbad, CA), PC2 reaction
buffer (50 mM Tris–HCl pH 9.1, 16 mM ammonium
sulfate, 3.5 mM magnesium chloride, and 150 μg/mL BSA)
(AB Peptides, St. Louis, MO), 500 μM dNTPs (Clontech,
Mountain View, CA), and 5 mM DTT (Life Technologies
Corporation, Carlsbad, CA). The RNA was denatured at
65°C for 5 min, followed by ramping extension tempera-
tures at 25°C for 10 min, 42°C for 60 min, 50°C for 30 min,
55°C for 30 min, and 70°C for 15 min.
Amplification of HCV via nested PCR
The cDNA from the RT reaction was diluted 1:1 into a
40 μL PCR1 reaction mixture, containing PC2 reaction
buffer (AB Peptides, St. Louis, MO), 200 μM dNTPs
(Clontech, Mountain View, CA), 1.5 M betaine (Sigma
Aldrich, St. Louis, MO), 2.56 units Klentaq DNA poly-
merase (AB Peptides, St. Louis, MO), 1.28 units pfu
DNA polymerase (Stratagene, La Jolla, CA), and 400 μM
each subtype-specific primer (Table 1). The PCR1 reac-
tion was incubated at 94°C for 2 min, followed by
30 cycles at 94°C for 15 sec, 68°C −0.5°C/cycle (“touch-
down” PCR) for 20 sec, followed by an incubation at
68°C for 12 min. The completed PCR1 reaction was
diluted 1:10 into a second PCR mixture (PCR2, 50 μL).
The reaction composition and PCR cycling parameters
were identical to the PCR1 reaction, with the following
changes; 3.2 units Klentaq DNA polymerase, 1.6 units of
Pfu DNA polymerase, and nested subtype-specific pri-
mers were utilized (Table 1).
Preparation of sample for sequencing
The PCR2 product (8991 bp) was analyzed and verified by
agarose gel electrophoresis, and purified using the QIA-
quick 96 PCR Purification kit (QIAGEN, Valencia, CA).
The purified PCR2 product was subsequently quantified
using a NanoDrop 8000 Spectrophotometer (Thermo
Scientific, Hudson, NH) prior to sequence analysis.Abbreviations
bp: Base pair; cDNA: Complementary DNA; DAA: Direct-acting antiviral;
dNTP: Deoxyribonucleotide triphosphate; DTT: Dithiothreitol; LLOD: Lower
limit of detection; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; IU/
mL: International units per milliliter; NS: Nonstructural; RBV: Ribavirin; RT-
PCR: Reverse-transcriptase polymerase chain reaction; tRNA: Transfer RNA;
UTR: Untranslated region.
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